Oncogene:前列腺癌中FRMD6具有抑制肿瘤的功能

2020-12-16 AlexYang MedSci原创

现有的前列腺癌(PC)预后工具不是最优的,但可能通过更好地了解驱动肿瘤侵袭性的基因来改善。

现有的前列腺癌(PC)预后工具不是最优的,但可能通过更好地了解驱动肿瘤侵袭性的基因来改善。

最近,有研究人员鉴定了FRMD6(包含FERM结构与的蛋白6)是PC中一个异常超甲基化和显著下调的基因。在两个大型PC患者队列中,FRMD6的低表达与术后生化复发相关。在PC细胞系的过表达和CRISPR/Cas9敲除实验中,FRMD6能够抑制生存力、增殖、细胞周期进展、克隆形成、3D球体生长和肿瘤异种移植生长。转录组、蛋白质组和磷酸蛋白质组分析显示,FRMD6敲除后Hippo/YAP和c-MYC信号富集。连通图分析和药物再利用实验确定了pyroxamide可作为FRMD6缺失PC细胞的一种新的潜在疗法。最后,研究人员在ROSA26小鼠前列腺中建立了正交的Frmd6和Pten,或仅Pten(对照)敲除。12周后,Frmd6/Pten双基因敲除表现出高级别前列腺上皮内瘤变(HG-PIN)和过度增殖,而Pten单基因敲除仅出现常规PIN病变,并表现出较低程度的增殖。

FRDM6抑制3D球状瘤和异种移植肿瘤的生长

最后,研究人员指出,他们的研究确定了FRMD6为PC中的新肿瘤抑制基因和预后生物标志物候选基因

原始出处:

Jakob Haldrup, Siri H. Strand, Clara Cieza-Borrella et al. FRMD6 has tumor suppressor functions in prostate cancer. Oncogene. Nov 2020

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2076681, encodeId=bd9e20e6681aa, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Sep 18 03:34:06 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049351, encodeId=2aae20493513a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 31 13:34:06 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558208, encodeId=17fc155820855, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Dec 18 12:34:06 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040908, encodeId=cd5710409081c, content=前列腺癌相关研究,学习了,谢谢williamhill asia , beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 17 00:34:06 CST 2020, time=2020-12-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2076681, encodeId=bd9e20e6681aa, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Sep 18 03:34:06 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049351, encodeId=2aae20493513a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 31 13:34:06 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558208, encodeId=17fc155820855, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Dec 18 12:34:06 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040908, encodeId=cd5710409081c, content=前列腺癌相关研究,学习了,谢谢williamhill asia , beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 17 00:34:06 CST 2020, time=2020-12-17, status=1, ipAttribution=)]
    2021-03-31 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=2076681, encodeId=bd9e20e6681aa, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Sep 18 03:34:06 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049351, encodeId=2aae20493513a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 31 13:34:06 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558208, encodeId=17fc155820855, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Dec 18 12:34:06 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040908, encodeId=cd5710409081c, content=前列腺癌相关研究,学习了,谢谢williamhill asia , beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 17 00:34:06 CST 2020, time=2020-12-17, status=1, ipAttribution=)]
    2020-12-18 zsyan
  4. [GetPortalCommentsPageByObjectIdResponse(id=2076681, encodeId=bd9e20e6681aa, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Sep 18 03:34:06 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049351, encodeId=2aae20493513a, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Mar 31 13:34:06 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558208, encodeId=17fc155820855, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Dec 18 12:34:06 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040908, encodeId=cd5710409081c, content=前列腺癌相关研究,学习了,谢谢williamhill asia , beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 17 00:34:06 CST 2020, time=2020-12-17, status=1, ipAttribution=)]
    2020-12-17 misszhang

    前列腺癌相关研究,学习了,谢谢williamhill asia

    0

相关威廉亚洲官网

Oncogene:Plectin是前列腺癌生长和转移的调节因子

前列腺癌每年造成3万多美国人死亡,主要归因于无法治愈的转移性疾病。

Eur J Cancer:雄激素剥夺疗法联合放疗治疗中危前列腺癌的3期临床试验结果

雄激素剥夺疗法联合放疗在中危前列腺癌中的作用仍然存在争议,特别是对于接受剂量递增放疗的患者。本研究比较了接受ADT和两种不同剂量RT治疗的IRPC患者与单纯放疗的患者预后。

Br J Cancer:miR-199b-5p-DDR1-ERK信号通路介导EMT进程抑制前列腺癌的转移

前列腺癌(PCa)作为西方国家男性中最常被诊断出的恶性肿瘤之一,是癌症相关死亡的第二大主要原因。2018年,全球约有130万新确诊PCa病例。在中国,前列腺癌的发病率和死亡率逐年增加。

Prostate Cancer P D:全基因组关联研究确定了孕激素受体在良性前列腺增生症风险中的作用

良性前列腺增生(BPH)是常见的非癌性前列腺增生,通常伴有下尿路症状(LUTS),能够导致复杂的泌尿、膀胱或肾脏疾病。随着年龄的增长,大多数老年男性会受到BPH的影响。

Eur Urol:ATM缺失的晚期前列腺癌:PARP和ATR抑制剂

之前的研究在转移性前列腺癌(PC)中发现了有害的ATM变异;PARP抑制对该亚型前列腺癌具有抗肿瘤活性,但只有一些ATM缺失的PC有响应。

Prostate Cancer P D:转移去势抵抗性前列腺癌患者中CTCs和tdEVs的自动计数和表型特征分析

尽管大多数转移去势抵抗性前列腺癌(mCRPC)患者最初受益于雄激素受体信号转导抑制剂(ARSi)的治疗,但不可避免地出现耐药性。最近,有研究人员调查了自动循环肿瘤细胞(CTC)和肿瘤源性细胞外囊泡(t